

July 23, 2025

To

Listing Department,

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza,

Bandra Kurla Complex, Bandra (E),

MUMBAI -400 051

Company Code No. AUROPHARMA

To

The Corporate Relations Department

BSE LIMITED

Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street,

MUMBAI -400 001

Company Code No. 524804

Dear Sir / Madam,

Sub: Intimation of Board Meeting.

Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that a Meeting of the Board of Directors of the Company will be held on **Monday**, **August 4, 2025**, to consider and approve, inter alia, the following:

- 1. Standalone & Consolidated Unaudited Financial Results of the Company for the first quarter ended June 30, 2025, and
- 2. Payment of Interim Dividend, if any, for the financial year 2025-26.

Further to our letter dated June 26, 2025, informing about the closure of Trading Window of the Company from July 1, 2025 until 48 hours from the date of declaration of the Unaudited Financial Results of the Company for the first quarter ended June 30, 2025, we inform you that the Trading Window will remain closed up to August 6, 2025 and shall be re-opened on August 7, 2025.

Please take the information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B. Adi Reddy Company Secretary

AUROBINDO PHARMA LIMITED

(CIN: L24239TG1986PLC015190)

www.aurobindo.com

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.